AUG 31, 2020 4:36 AM PDT

A Treatment Avenue Opens for a Rare Disorder

WRITTEN BY: Carmen Leitch

Krabbe disease or globoid cell leukodystrophy is a rare disorder that affects about one in every 100,000 infants. It's caused by a mutation in a gene called GALC, which encodes an enzyme called galactosylceramidase. This incurable condition, which destroys the insulation surrounding nerve cells, is usually fatal to patients before age two.

Image credit: Pxhere

The disorder also affects dogs, who get symptoms starting around six weeks of age. It's also fatal for them; the dogs only survive for a few months after the onset of symptoms. Researchers have now used a canine model of Krabbe disease to show that gene therapy can eliminate the symptoms of the disease. Reporting in the Journal of Clinical Investigation (JCI), the scientists found that dogs that received the therapy lived to be at least four years old, apparently with no significant side effects.

"This disease has no good therapy," said senior study author Charles Vite, a professor of neurology. "We've been looking at this disease in dogs since the 1990s, but it was really the shift over to a new gene therapy vector that gave us a chance to treat it with a big effect on the nervous system."

Cells contain small organelles called lysosomes, they are sacs that contain digestive enzymes. Krabbe disease is a lysosomal storage disorder. Normally, the enzyme encoded by the GALC gene would break down lipids, but a mutated GALC enzyme cannot, so stuff builds up inside of the lysosomes. In the case of Krabbe disease, that disrupts the insulation or myelin surrounding nerve cells, which alters nerve signaling. The disorder leads to neurological symptoms, including blindness, deafness, and paralysis.

A risky bone marrow transplant in an infant patient's first month can help relieve the disorder, but it only works in thirty percent of those treated. "A new treatment is really needed," Vite said.

As with any gene therapy, getting the therapeutic materials to the right place in the body and cells poses a challenge. In this work, the scientists successfully used a viral vector that has been used in other gene therapies, the AAV9 vector, which seems likeliest to gain FDA approval. They tried using high and low doses of the therapy at various ages.

"We decided we would inject into the spinal fluid via the back of the head, which is the most effective means of getting to the brain," noted Vite.

The most benefit was seen in dogs that were given a high dose of gene therapy before they showed symptoms; they had more myelination in their brains, and the myelination in their peripheral nervous system was maintained (even though the therapy was injected into the central nervous system).

"That was a huge surprise for us; that injecting a gene therapy in the spinal fluid can positively affect both the central and the peripheral nervous system was really exciting," Vite said.

There was still a benefit for dogs that were treated after symptoms started. Though they had an intermediate form of the disease, they lived significantly longer than dogs that had not gotten any therapy. It shows that trials will have to be careful about the proper dose.

Follow-up studies will examine the molecular impacts of the therapy, as well as how to ensure both dogs and children receive the correct dose. Vite suggested that since this therapy triggered some improvement in the peripheral nervous system, the approach might be useful for other disorders.

"The hope is to use the model as a method to understand the mechanisms at work in peripheral nerves and how we can target peripheral neuropathies," said Vite.

Sources: AAAS/Eurekalert! via University of Pennsylvania, Journal of Clinical Investigation

About the Author
BS
Experienced research scientist and technical expert with authorships on over 30 peer-reviewed publications, traveler to over 70 countries, published photographer and internationally-exhibited painter, volunteer trained in disaster-response, CPR and DV counseling.
You May Also Like
AUG 18, 2022
Genetics & Genomics
Some Epigenetic Tags can be Passed Down From Mothers to Offspring
AUG 18, 2022
Some Epigenetic Tags can be Passed Down From Mothers to Offspring
The human genome holds thousands of genes, and gene expression has to be carefully controlled in cells; the right gene m ...
SEP 14, 2022
Genetics & Genomics
Neurodegeneration is Linked to Jumping Genes
SEP 14, 2022
Neurodegeneration is Linked to Jumping Genes
Scientists are beginning to reveal the secrets of the long, repetitive sequences in the human genome that were once writ ...
SEP 26, 2022
Genetics & Genomics
Thousand-Year-Old Poop Teaches us About an Ancient Parasite
SEP 26, 2022
Thousand-Year-Old Poop Teaches us About an Ancient Parasite
Parasitic whipworm eggs have been isolated from fossilized human fecal samples that were estimated to be over 7,000 year ...
OCT 29, 2022
Coronavirus
Extreme Evolution - WHO Now Tracking Over 300 Omicron Subvariants
OCT 29, 2022
Extreme Evolution - WHO Now Tracking Over 300 Omicron Subvariants
As the pandemic has progressed, different variants of SARS-CoV-2 have arisen. Now Omicron subvariants are proliferating, ...
NOV 02, 2022
Genetics & Genomics
A Mildly Pathogenic Mutation, Inherited Over 800 Years, Traces Back to One Person
NOV 02, 2022
A Mildly Pathogenic Mutation, Inherited Over 800 Years, Traces Back to One Person
Scientists have recently identified a genetic mutation that causes epilepsy, and carried by at least 90 people. These mu ...
NOV 12, 2022
Earth & The Environment
45,000-Year-Old Human DNA Divulges Human Evolution Secrets
NOV 12, 2022
45,000-Year-Old Human DNA Divulges Human Evolution Secrets
In a recent study published in Nature Ecology & Evolution, an international team of researchers led by the Universit ...
Loading Comments...